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Abstract
Background: Mood and anxiety disorders are highly prevalent and have a large impact on the lives
of the affected individuals. Therefore, optimal treatment of these disorders is highly important. In
this study we will examine the effectiveness of a stepped care program for primary care patients
with mood and anxiety disorders. A stepped care program is characterized by different treatment
steps that are arranged in order of increasing intensity.
Methods: This study is a randomised controlled trial with two conditions: stepped care and care
as usual, whereby the latter forms the control group. The stepped care program consists of four
evidence based interventions: (1) Watchful waiting, (2) Guided self-help, (3) Problem Solving
Treatment and (4) Medication and/or specialized mental health care. The study population consists
of primary care attendees aged 18–65 years. Screeners are sent to all patients of the participating
general practitioners. Individuals with a Diagnostic and Statistical Manual of mental disorders (DSM)
diagnosis of major depression, dysthymia, panic disorder (with or without agoraphobia),
generalized anxiety disorder, or social phobia are included as well as individuals with minor
depression and anxiety disorders. Primary focus is the reduction of depressive and anxiety
symptoms. Both conditions are monitored at 8, 16 and 24 weeks.
Discussion: This study evaluates the effectiveness of a stepped care program for patients with
depressive and anxiety disorder. If effective, a stepped care program can form a worthwhile
alternative for care as usual. Strengths and limitations of this study are discussed.
Trial Registration: Current Controlled Trails: ISRCTN17831610.
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Background
Depressive and anxiety disorders are highly prevalent [1].
Currently, depressive disorders are the fourth disorder
worldwide in terms of disease burden, and will be the dis-
order with the highest disease burden in high-income
countries by 2030 [2]. Anxiety and depression can cause
serious functional impairment, reduced quality of life
[3,4], high levels of public service usage and huge eco-
nomic costs [5,6]. Comorbidity is high among psychiatric
disorders in general [1]. Almost half of the people who
have ever suffered from a psychiatric disorder have had
more than one. Comorbid anxiety is the rule rather than
the exception with up to 60% of the patients with major
depressive disorder also suffering from an anxiety disor-
der [7]. Because of this high comorbidity and the difficul-
ties in distinguishing the two disorders without extensive
diagnostic interviews, this study includes individuals with
depressive disorders as well as with anxiety disorders.
There are ongoing discussions regarding the effectiveness
of the management of common mental health problems
in general practice settings. Both anxiety disorders and
depression can be treated effectively by pharmacotherapy
as well as psychotherapy [8-15]. Although evidence based
clinical guidelines are available, initiation and adherence
to effective treatment are usually poor [16-19]. Mood and
anxiety disorders often remain unrecognised and there-
fore untreated in primary care [20]. Furthermore, it has
been demonstrated that even when depression has accu-
rately been recognized, still only few patients receive ade-
quate care [19]. According to several studies [21-23] many
patients receive antidepressants immediately after the
diagnosis was determined, however, only few patients
receive adequate dosage and duration of (antidepressant)
medication. Approximately 30% of depressed primary
care patients stop using antidepressant medications
within the first month of treatment, while only 40% reach
the recommended therapeutic dosage of antidepressant
medication [24]. It is also important to note that the
majority of primary care patients prefer psychotherapy as
a treatment [25]. Clearly, the gap between research find-
ings and clinical practice is wide in the management of
depression in primary care [26].
Through its objective of initiating interventions at the
right time and as adequately as possible, the stepped care
model could provide a solution for the problem of apply-
ing effective, evidence based care for depression and anx-
iety. Care is offered not earlier or more intense than
necessary and not later or less intense than needed
[27,28]. In a stepped care model, all patients start with an
evidence-based treatment of low intensity as a first step.
Progress is monitored and patients, who do not respond
adequately can 'step up' to a subsequent treatment of
higher intensity [29]. An important feature of the stepped
care model is that the model is self-correcting. Self-correct-
ing means that the results of treatments and decisions
about treatment provisions are monitored systematically
and where necessary changes are made ('stepping up') if
current treatments are not achieving significant health
improvement [27]. A care manager coordinates a stepped
care program, preferably a paraprofessional who supports
the primary care clinic handling psychiatric problems. In
The Netherlands the most likely candidate for this role is
a psychiatric nurse. This care manager coordinates the
monitoring of the patients, provides the first treatments in
the stepped care model and refers the patient to the appro-
priate mental health care specialist if necessary.
Although the stepped care model seems to be a promising
care model [27-30] to increase the effectiveness and effi-
ciency of the mental health system, its effectiveness com-
pared with care as usual (CAU) has not been studied yet
[27-29]. We will describe the protocol of a study on the
(clinical) effectiveness of this program versus care as usual
with patients who are diagnosed with a minor or major
mood and/or anxiety disorder.
Methods
Study design
This study is a randomised controlled trial. We recruit
patients by screening all patients of the participating GPs
during an inclusion period of 1,5 years. All patients with
a positive screen for depression and/or anxiety are
screened again after 4 to 6 weeks. Those with a second
positive screening (baseline) are contacted by telephone
for a diagnostic interview. During this interview all in- and
exclusion criteria are checked. Those who are eligible for
participation are being asked for informed consent to par-
ticipate in the study. All patients who give informed con-
sent are subsequently randomised to either (1) stepped
care or (2) care as usual. All patients are asked to fill out
questionnaires again after 8, 16 and 24 weeks. The study
protocol, information brochure and informed consent are
approved by the Medical Ethics Committee of the VU Uni-
versity Medical Center (registration number 2006/248).
Inclusion and exclusion criteria
We include adults aged 18 – 65 years with one or more of
the following DSM-IV diagnoses: major depression (sin-
gle episode or recurrent), dysthymia, panic disorder (with
or without agoraphobia), social phobia or generalized
anxiety disorder, including comorbid diagnoses. We also
include patients with a minor depression or a minor anx-
iety disorder. We use the DSM-IV research criteria to
define minor depression. The main difference between
the criteria of minor and major depression is that for
minor depression only two to four out of nine symptoms
have to be present, of which at least one has to be a core
symptom (depressed mood or markedly diminishedBMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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interest or pleasure in all, or almost all, activities). As there
are no DSM criteria, we define a minor anxiety disorder as
a score of 12 or more on the Hospital Anxiety and Depres-
sion Scale [31] and dysfunctioning in daily life (house-
hold, work and/or social relations). Exclusion criteria are
psychotic or bipolar disorder, current (< 2 months) treat-
ment (medical/psychotherapy) for psychological prob-
lems, prominent suicide ideation, severe alcohol
problems (> 20 on the Alcohol Use Disorders Identifica-
tion Test (AUDIT)[32], no motivation for treatment and
insufficient knowledge of the Dutch language.
Recruitment
Recruitment of GPs
In the present study we collaborate with two mental
health centers in Amsterdam (GGZ inGeest and Men-
trum). Both of these mental health centers employ psychi-
atric nurses and psychologists, who work for a few hours
per week in a GP practice. Usually, GPs refer patients to
these psychiatric nurses/psychologists for short-term
treatments. First we want to approach psychiatric nurses
and psychologists and secondly we want to invite the cor-
responding GPs to collaborate in this study.
Recruitment of patients
Patients are recruited by screening all patients of the par-
ticipating GPs during the inclusion period of 1,5 year. All
patients with a positive screen for depression and/or anx-
iety are assigned to a watchful waiting period of 4 weeks.
After 4 weeks every patient is screened again to exclude the
patients who recover spontaneously. This second screener
is the baseline questionnaire (T0) and is sent to each
patient together with general information about the
project and an informed consent form. Two weeks later
the patients are approached for a diagnostic interview
(Composite International Diagnostic Interview: CIDI)
[33] by telephone to check for in- and exclusion criteria.
Patients who meet the inclusion criteria and return their
informed consent are randomised.
Randomisation
Randomisation takes place at an individual level. Patients
are randomised into two groups, stratifying by care man-
ager and using blocks of 4 to prevent overburdening the
care managers. An independent researcher not involved in
the current project uses computer generated block ran-
domisation to produce sealed envelops. After every inclu-
sion the researcher opens a sealed envelop.
Intervention
The stepped care intervention consists of four steps: (1)
Watchful waiting. Patients with mood and anxiety disor-
ders often recover spontaneously over time [34]. In the
first step the patients receive no treatment for four weeks.
In this project, only patients who still show symptoms of
anxiety/depression after the watchful waiting period, are
included. They start with (2) Guided self-help. Guided self-
help starts with one 30 minute session with a care man-
ager. This session enables the care manager to check exclu-
sion criteria (e.g., severe psychopathology), to give
psychoeducation (e.g., advice on lifestyle) and to explain
the self-help interventions. In this study we have two dif-
ferent self-help interventions available. The first is a
generic intervention based on problem solving treatment,
which aims at patients with symptoms of mood and/or
anxiety disorders. The Dutch version of self-examination
therapy is called "Alles onder controle" and is available as a
book and through the Internet. The patient can choose to
get feedback by email or by telephone. In this study feed-
back is provided by coaches (members from the research
group) from the VU University. The focus of the feedback
is to guide the patient through the intervention by moti-
vating and activating them. When patients send their
assignments to their coach, they receive feedback within 3
working days. The second self-help intervention is specif-
ically aimed at patients with phobias and is based on
exposure therapy. In this course patients first have to
make a list of all the situations that provoke anxiety and
put them in order of intensity. Next they have to make a
plan to practice exposure to these situations based on this
anxiety hierarchy. This course takes six weeks to complete
and is only available as a book. Feedback is therefore pro-
vided by telephone. During the first session, the care man-
ager and the patient together decide which self-help
course is most suitable. Patients who do not recover using
self-help treatment start with (3) Problem Solving Treatment
(PST). PST is a short psychological intervention, 5 ses-
sions of 45 minutes each, provided by the care manager
[35]. The treatment protocol is based on 'Problem-solving
treatment for anxiety and depression: A practical Guide' by
Laurence Mynors-Wallis [36]. Recent studies show that
PST is an effective treatment for major depression as well
as for more general, emotional disorders containing
depressive and anxiety symptoms [35,37-42]. Training in
PST was given by a problem solving treatment expert in a
two-day course followed by weekly group supervision ses-
sions. Patients who are unresponsive to this treatment will
proceed to the last step of the stepped care program (4)
Pharmacotherapy and/or specialized mental health care. In
case patients do not recover from PST they have one more
session with the care manager to discuss the next step:
either pharmacotherapy or more specialized mental
health care. In case a patient chooses pharmacotherapy,
the care manager sets up an appointment for the patient
with the GP. In case the patient chooses specialized men-
tal health care, the care manager sets up an appointment
with a mental health care specialist.BMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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Exceptions
Even though there is no clear evidence that patients with
more severe symptoms of anxiety or depression do not
benefit from low intensity (self-help) interventions, we
decided that patients with more severe disorders should
be referred to more specialized mental health care and/or
pharmacotherapy directly and skip the preceding steps.
Severity of the disorders is based on questions about daily
functioning on the Work and Social Adjustment Scale
(WSAS) [43]. If the patient experiences extreme dysfunc-
tioning (score of 8 or higher) on minimal three of the four
domains (household, work, social relations and social
activities) he will be directed immediately to the fourth
step of the stepped care program.
Care as Usual
Patients randomised to the 'care as usual' will be informed
about this outcome. They are informed that they can
choose to find (mental) health care and are allowed to
discuss this with their GP.
Assessments and definition of recovery
After each step in the stepped care intervention, patients
are monitored: after 8 weeks (T1), 16 weeks (T2) and 24
weeks (T3). During each assessment we measure depres-
sive symptoms, symptoms of anxiety and daily function-
ing. Recovery is defined as a score below the cut-off score
on all three of the following questionnaires: having a
score of less than 14 on the Inventory of Depressive Symp-
tomatology (IDS) [44], a score of less than 8 on the Hos-
pital Anxiety and Depression Scale [31] and a score of less
than 6 on the WSAS [43]. This definition of recovery is
based on several studies [44-48]. On account of the out-
come of the monitor, we decide whether the patient is
recovered or is 'stepping up' to the next step in the stepped
care model.
Instruments
Screening
Kessler Psychological Distress Scale (K10)
The Kessler Psychological Distress Scale (K10) [49] is used
as screener in this study. The K10 consists of 10 items
measuring the amount of distress and severity of the psy-
chological symptoms. Due to outstanding psychometric
characteristics, the K10 is a worldwide used screener [49-
51]. The 10 items are scored from 1 to 10 and a sum-score
can range between 10 and 50. The cut-off score is 20. The
K10 measures depression and since this study also
includes anxiety, we use an extended version of the K10,
developed by The Netherlands Study of Depression and
Anxiety (NESDA, http://www.nesda.nl). The extended
version contains five extra items for anxiety. The anxiety
items can only be answered "yes" or "no". Compared to
the K10, the extended K10 has a higher sensitivity and
specificity for detecting both depressive and anxiety disor-
ders [52].
Respondents screen positive when they score higher than
the cut-off score of 20 and/or reported at least one "yes"
on the anxiety items. Respondents with a negative
screener were excluded from the study.
Composite International Diagnostic Interview (CIDI)
The CIDI (version 2.1), a structured interview developed
by the World Health Organisation [33], enables trained
interviewers to assess psychiatric diagnosis defined in the
Diagnostic and Statistical Manual of the American Psychi-
atric Association, 4th edition [53]. The assessment typi-
cally lasts 30–75 minutes, depending on the mental state
of the respondents [54]. In this study, current mental sta-
tuses within the last two months will be considered.
Primary outcome
Depressive symptoms
We will use the Inventory of Depressive Symptomatology
(IDS) to measure depressive symptoms. The IDS consists
of 26 items and the total score varies between 0 and 79.
Scores below 14 indicate absence of depressive symptoms.
We use this cut-off score as an indication of recovery from
depressive symptoms [44,46]. Internal consistency is high
for the IDS with Cronbach's alpha being .92 [44].
Anxiety symptoms
For identifying anxiety disorders we will use the Hospital
Anxiety and Depression Scale (HADS) [31], which is usu-
ally used to identify anxiety disorders among patients in
non psychiatric settings. The HADS consists of 7 items.
Item responses are on a 0 to 4 scale (0="none" and higher
ratings reflect greater degrees of symptom severity). Total-
scores range from 0 to 21. The HADS showed good homo-
geneity and reliability, with Cronbach's alpha ranging
from .81 to .84 in different normal and clinical Dutch
samples [55].
Dysfunctioning
We will measure daily functioning of the patient via four
questions of the Work and Social Adjustment Scale
(WSAS) [43,56]. The patient gives an estimate, on a scale
from 1 to 10, of the perceived dysfunctioning in daily live.
The questions contain four domains: household, work,
social relations and social activities.
Secondary outcome
Quality of life
Quality of life is measured through the MOS Short-Form
general health survey (SF-20) which identifies the health
related quality of life [57]. This self-report questionnaire
(20 items) consists of six scales covering mental health,
perceived health (mental and physical), social and roleBMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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functioning, physical functioning and pain. A high score
on the SF-20 indicates a high level of functioning, except
for the subscale physical pain where a higher score indi-
cates a higher level of pain. The alpha of the scales varies
between .80 and .91 [57,58]. Quality of life is furthermore
assessed using the EuroQol Questionnaire (EQ5D) [59],
which is a validated tool for measuring general health
related quality of life. It consists of five items (mobility,
self-care, usual activities, pain/discomfort and anxiety/
depression), each of which is rated as causing 'no prob-
lems', 'some problems' or 'extreme problems'. The EQ5D
distinguishes 486 unique health states. Each unique
health state has a utility score which ranges from 0 (poor
health) to 1 (perfect health). EuroQol also contains a Vis-
ual Analogue Scale (VAS) on which patients rate their own
health between 0 (worst imaginable health state) and 100
(best imaginable health state). Recently, a study in The
Netherlands measured and valuated the EQ-5D in a
national setting, resulting in the 'Dutch EQ-5D tariff' [60].
This tariff is used to calculate utilities for EQ-5D health
states for cost-utility analyses of Dutch health care pro-
grammes and treatments.
Symptoms
The Four Dimensional Symptom Questionnaire (4DSQ)
is developed for GPs to distinguish depression, anxiety
and somatisation from more general distress [61]. The dis-
tress scale exists of 16 items and scores range from 0 – 32,
the depression scale exists of 6 items and scores range
from 0 – 12, the anxiety scale exists of 12 items and scores
range from 0 – 24 and the somatisation scale exists of 16
items where scores range from 0 – 31. A higher score on
the symptomatology indicates more serious complaints.
The 4DSQ is a valid self-report questionnaire [61].
Alcohol use
The Alcohol Use Disorder Identification Test (AUDIT)
[32] is a list of 10 questions about alcohol use. This test
measures three different domains: quantity and frequency
of alcohol use, the symptoms of alcohol dependency and
the negative reactions on/consequences of alcohol use
[62]. The score ranges from 0 – 40. A score of 9 or higher
indicates a risk of an alcohol problem and a score of 13
and higher indicates the presence of an alcohol problem
[63]. A study of Maisto et al. [62] shows that the AUDIT is
a reliable and valid instrument. A score of 20 or higher on
the AUDIT means exclusion from this study. Indices of
internal consistency, including Cronbach's alpha and
item total correlations, are generally in the .80's [64].
Personality
The Neuroticism, Extraversion, Openness to New Experi-
ence-Five Factor Inventory (NEO-FFI) is a questionnaire
that contains 60 items on the five personality domains;
neuroticism, extraversion, openness to experience, agreea-
bleness and conscientiousness. The item responses are
given on a 0 – 5 scale (strongly disagree, disagree, neutral,
agree, strongly agree) [65]. A study of Weinstock and
Whisman [66] shows that neuroticism is commonly man-
ifested together with depression and anxiety disorders,
therefore we only use those 12 items that identify neurot-
icism. Internal consistency ranges from .68 to .86 [67].
Health care utilisation
We use the Trimbos and iMTA questionnaire on Costs
associated with Psychiatric illness (TiC-P) [68] to collect
data on direct and indirect costs from the patients. The
first part of the TiC-P measures the amount of medical
care received by the participants, while the second part
measures work productivity. We are going to confirm the
actual received care, by checking the patients' care status
and received care (e.g., medication, number of contacts in
primary care and referral policy) during the stepped care
project at the general practice settings and the specialized
mental health care centers.
Health related absenteeism
For the measurement of health related absenteeism, we
used the earlier mentioned TiC-P.
Costs
We will examine the societal costs which are based on the
health care utilisation and health related absenteeism.
Satisfaction with care
This is measured via the QUOTE, which stands for Quality
Of care Through the patient's Eyes. This questionnaire
gives insight in the patient's opinions and believes about
the quality of the received care [69]. There are different
questionnaires for different diseases. For our study we use
the questionnaire for anxiety and depression developed
by NIVEL. In the first part of the QUOTE the perceived
importance of care-aspects in anxiety and depression are
measured. This part contains of 18 items and item-
responses are on a 0 – 4 scale (not important – extremely
important). The second part of the QUOTE consists of 18
items on the patients experience with the last received
care. Item-responses on the second part are on a 0 – 5
scale (yes – no: or no experience).
Mastery
We assess the amount of perceived control through the
Pearlin Mastery Scale [70]. This scale has 7 items measur-
ing how much an individual perceives having control over
things in his or her life. Items are rated on a 4-point scale
with higher scores indicating more perceived control.
Outcome-scores range from 7 – 35. The questionnaire has
good psychometric properties [70] (Table 1).BMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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Table 1: Overview of the selected instruments
Time of measurement
Aim Measurement Screening Baseline
(pre-test)
T0
T1 T2 T3
Demographic variables Sex X X X X X
Date of birth X X X X X
Native country X
Education X
Income X
Marital status X
Motivation X (T)
Screening
Symptoms of depression and anxiety Extended K10 X X (T)
Primary Outcome
Symptoms of depression IDS X X X X
Symptoms of anxiety HADS-A X X X X
Secondary Outcome
Diagnosis CIDI X (T) X (T)
(Dys) Functioning WSAS X (T) X X X
Quality of life SF 20 X X X X
Symptomatology 4DKL X X
Alcohol Use AUDIT XBMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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Sample Size
A meta-analysis on the effects of psychological treatment
on patients with sub-clinical depression shows an effect
size of 0.40. Based on a power of 0.80 in a two-tailed test
and an alpha of 0.05, we need 100 patients in each condi-
tion. Therefore, the total sample size is set at 200.
Statistical Analysis
All analyses will be conducted according to the intention-
to-treat principle. All respondents who have been ran-
domised will be included in the analyses examining the
effects of the intervention. Missing data will be imputed
using regression imputation. The effectiveness of the
stepped care program is measured via the primary out-
comes: the HADS (anxiety) and IDS (depression). It is
useful to know not only wether the effectiveness is statis-
tically significant, We will use Cohens' d [71] to measure
the size of the effect. Furthermore, GEE-analysis will be
used to examine differences in speed of recovery between
the two groups [72]. Additionally, we will report the per-
centage of patients who have recovered at the moment of
the last assessment. In order to do so we will calculate the
relative risk.
Discussion
This paper describes the design of a study to investigate
the effectiveness of stepped care for patients with minor
and/or major depressive and anxiety disorders in compar-
ison with care as usual in general practice. The following
four steps are included in the stepped care model: watch-
ful waiting, guided self-help, PST and pharmacotherapy
and/or referral to mental health care. All these interven-
tions are evidence based but there is a lack of studies
regarding the effectiveness of stepped care as a whole.
Results of this study could offer encouragement for the
implementation of an effective stepped care model.
A major strength of this study is that it is a pragmatic ran-
domised trial. In a pragmatic trial, patients and therapists
are the same as those seen in daily practice. This means
that the sample of patients may be quite heterogeneous
(may have mild to severe depression/anxiety with or with-
out psychiatric or somatic co-morbidity) and that the
therapists (psychiatric nurses or psychologists) have aver-
age qualifications (instead of top level therapists from an
academic centre). This enhances external validity which
means that the results of this study will reflect the 'real'
effects of daily practice. If an intervention is shown to
have a significant beneficial effect in a pragmatic trial then
it has been shown not only that it can work, but also does
work in real life [73].
This advantage of the study has also some risks. First of all,
it is difficult to maintain treatment integrity when con-
ducting a study in day-to-day clinical practice and using
personell not specifically hired for research. We hope to
minimize this limitation by organizing strict supervision
of the care managers.
Secondly, it is possible that there is a bias in our GP
recruitment. To conduct this study, we need GPs who
work together with a psychiatric nurse. This could mean
Perceived health EuroQol X X X X
Neuroticism NEO-FFI X
Costs of care TIC-P X X X X
Quality of care Quote X
Mastery Pearlin Mastery Scale X
Suicidal risk MINI suicide X (T)
Table 1: Overview of the selected instruments (Continued)BMC Health Services Research 2009, 9:90 http://www.biomedcentral.com/1472-6963/9/90
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that these particular GPs are aimed at mental health prob-
lems more than their colleagues who work without psy-
chiatric nurse in their practice. If the GPs in our study pay
more attention to mental health problems then GPs with-
out psychiatric nurses, then our care as usual might be
more adequate then care as usual in general.
Another limitation of our study could be the fact that we
choose to recruit people with a diagnosis who do not
receive any form of care and/or medication. There is a pos-
sibility that these patients have visited the GP before, but
were not recognized as mental health patients. These
patients might differ in a number of aspects from those
who were recognized as mental health patients by their
GP. It is possible that this leads to selection bias. To exam-
ine this we will conduct a non-response research.
It is widely acknowledged that depression recognition and
management in primary care can be improved. As a con-
sequence many collaborative care models, or disease
management strategies, have been developed in recent
years. The core elements of these care models are (1) an
enhanced case management role for nonmedical special-
ists such as practice nurses and (2) integrated working
relationships between primary care and specialist/second-
ary services [74]. In general these models seem to improve
depression treatment [75]. Previous research into a partly
implemented stepped care model in secondary services
has shown cost-effectiveness compared to care as usual
[29,76]. However, to our knowledge, our trial is the first
trial with a fully implemented stepped care model for
depression and anxiety treatment in primary care com-
pared to care as usual.
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